Update on Farxiga COVID-19 DARE-19 Phase III trial
12 April 2021 07:00 BST Update on the DARE-19 Phase III trial for Farxiga in COVID-19 AstraZeneca and Saint Luke's Mid America Heart Institute today announced high-level results of the primary analysis from the DARE-19 Phase III trial assessing the potential of Farxiga (dapagliflozin) to treat patients hospitalised with COVID-19 who are at risk of developing serious complications. The trial did not achieve statistical significance for the primary endpoint of prevention measuring organ dysfunction and all-cause mortality, and the primary endpoint of recovery measuring a